Lexicon Pharmaceuticals (LXRX) Cash from Operations Growth (3y) (2013 - 2026)
Lexicon Pharmaceuticals (LXRX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 34.32% |
| 10 | Lexicon Pharmaceuticals | 922.55 Mn | 751.90 Mn | 20.99 Mn | 22.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.47% |
| Dec 31, 2025 | 7.21% |
| Sep 30, 2025 | -7.03% |
| Jun 30, 2025 | 39.18% |
| Mar 31, 2025 | -23.18% |
| Dec 31, 2024 | 1.99% |
| Sep 30, 2024 | -46.22% |
| Jun 30, 2024 | -30.42% |
| Mar 31, 2024 | -29.89% |
| Dec 31, 2023 | -13.87% |
| Sep 30, 2023 | -1.01% |
| Jun 30, 2023 | 6.28% |
| Mar 31, 2023 | -12.75% |
| Dec 31, 2022 | 3.99% |
| Sep 30, 2022 | -28.10% |
| Jun 30, 2022 | 3.17% |
| Mar 31, 2022 | 2.95% |
| Dec 31, 2021 | 5.59% |
| Sep 30, 2021 | 8.22% |
| Jun 30, 2021 | 25.32% |